Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.

Abstract excerpt

The tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are becoming the first line of therapy for advanced non-small cell lung cancer (NSCLC). Acquired mutations in EGFR account for one of the major mechanisms of resistance to the TKIs. Three generations of EGFR TKIs have been used in clinical applications. AZD9291 (osimertinib; Tagrisso) is the first and only FDA approved...

Topics

Join the communities discussing this publication.

• Acrylamides
• Aniline Compounds
• Carcinoma, Non-Small-Cell Lung
• Drug Resistance, Neoplasm
• Protein Kinase Inhibitors